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Each year approximately 1 million people are diagnosed with 
colorectal cancer (CRC) worldwide, but the incidence varies 
greatly. The disease is commonest among Japanese men, and 
lowest in Africa.1 Colorectal cancer is reported to have a low 
incidence in South Africa, although it appears to have increased 
over the past decade. CRC is now the fourth commonest cancer in 
men in South Africa, and the third commonest in women.2,3
Hereditary non-polyposis colorectal cancer (HNPCC) is 
the commonest inherited colorectal cancer. It is an autosomal 
dominant condition caused by germline mutations of the 
mismatch repair genes, and is characterised by young-onset CRC 
as well as extracolonic malignancies.4,5 These tumours display 
microsatellite instability (MSI-h), and have distinctive pathological 
features. The suggestive clinical and pathological features of these 
tumours are summarised in the revised Bethesda criteria for the 
diagnosis of HNPCC6 (Table I). The purpose of these criteria is to 
select patients for genetic testing for HNPCC. 
Previous studies of colorectal cancer in black South Africans 
have reported that colorectal cancer affects a disproportionately 
large number of younger patients,7,8 and that pathological and 
immunohistochemical features suggestive of HNPCC were 
Summary
Aim. The purpose of this study was to determine the incidence 
of colorectal cancer (CRC) in the Northern Cape province of 
South Africa, and to identify patients with histological and 
demographic features suggestive of hereditary non-polyposis 
colon cancer (HNPCC).
Method. This is a retrospective review of all cases of prima-
ry adenocarcinoma of the colon or rectum diagnosed by the 
two pathology laboratories operating in the Northern Cape 
between January 2002 and February 2009. Demographic 
data were collected, as well as pathological staging of the 
tumours and histological features suggestive of HNPCC (ac-
cording to the revised Bethesda guidelines for microsatellite 
instability testing). Population census data for the Northern 
Cape were obtained from Statistics South Africa.
Results. The annual incidence of CRC in the Northern 
Cape was 3.7/100 000 population (3.5/100 000 for men and 
3.9/100 000 for women). The median age at which colorectal 
cancer was diagnosed was 59 years (range 16 - 90 years). 
On pathological and demographic criteria, 75/206 (36%) of 
the patients met at least one of the criteria of the revised 
Bethesda guidelines for microsatellite instability testing.
Conclusion. CRC is rare in the Northern Cape, and one-
third of the patients had demographic or tumour histological 
features suggestive of HNPCC. 
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common in CRC in this group of patients.7 In the mid-1980s the 
first familial cases of CRC to be reported in South Africa were 
identified in Kleinsee, a remote town in the Northern Cape. The 
family was found to have HNPCC, with a unique mutation of the 
hMLH1 gene. Since then we have identified over 1 500 subjects 
(many of whom live in the Northern Cape) from a number of 
different families as being at risk for HNPCC on the basis of their 
family trees. We have identified 13 different germline mismatch 
repair gene mutations in these subjects, but the mutations in the 
majority of these subjects remain unknown.9,10
The Northern Cape has an estimated population of just over 1.1 
million people and is the least populated province of South Africa, 
with an average of 3 persons per square kilometre.11 The incidence 
of colorectal cancer in this area has not been documented, and the 
prevalence of HNPCC in the population is unknown.
The purpose of this study was to determine the incidence of 
colorectal cancer in the Northern Cape, and to identify patients 
with histological and demographic features of HNPCC in order to 
guide further genetic screening in this population.
Methods
All cases of primary adenocarcinoma of the colon or rectum 
diagnosed in the Northern Cape province of South Africa between 
January 2002 and February 2009 were retrospectively reviewed. 
All pathology reports of colorectal adenocarcinoma from both 
pathology laboratories operating in the Northern Cape (the 
National Health Laboratory Services (NHLS), which provides 
a service to the state hospitals, and Pathcare, which serves the 
private sector) were requested. The patients from the state and 
private health systems were analysed separately, as this is a 
surrogate marker for affluence in the South African health care 
system.
Tumours were staged according to the Duke’s staging 
system12 (staging was based only on the histological findings 
– no information regarding distant metastases was available 
except when metastases were biopsied or resected for 
histological examination), and graded as poorly, moderately or 
well differentiated. The site of the tumour was noted, as were 
histopathological features suggestive of microsatellite instability. 
Wherever possible the address and postal codes of the subjects 
were obtained, and any subjects found to be living outside the 
Northern Cape were excluded from the study. In the absence 
of any information to the contrary, subjects were assumed to 
be residents of the Northern Cape if they had undergone their 
colorectal cancer operations in that area. 
When a patient was diagnosed with a metachronous colon 
cancer within the study period, only the first cancer was included 
in the study.
To calculate the incidence of colorectal cancer, census data 
for the population of the Northern Cape were obtained from 
Statistics South Africa.13 In order to allow comparison with cancer 
rates in populations with different age demographics, the age- 
standardised rate (ASR) for colorectal cancer was calculated using 
the World Standard Population.14
Statistics 
Statistical analysis was performed using Statistica 8 software. 
Categorical data were compared using the chi-square or two-sided 
Fisher’s exact tests as appropriate. Normally distributed continuous 
data were compared using Student’s t-test and continuous data 
with a skewed distribution using the Mann-Whitney U-test. A 
value of p<0.05 was considered to be significant.
Ethics
Anonymity of the subjects was assured and patient information 
was only available to the investigators. Ethical approval for the 
study was granted by the Health Sciences Faculty Research Ethics 
Committee of the University of Cape Town. 
Results
We identified 206 patients with adenocarcinoma of the colon or 
rectum between January 2002 and February 2009. Of these, 101 
were men and 105 women. 
Incidence of colorectal cancer
Records could only be obtained from the Pathcare laboratory for 
the period 2006 - 2008, so the incidence of colorectal cancer in 
the Northern Cape could only be calculated for that time. During 
that period, 113 patients were diagnosed with colorectal cancer 
(73 patients (65%) in the public sector, and 40 (35%) in the private 
sector). The population of the Northern Cape in 2007 was 1 102 
200, so the annual incidence of colorectal cancer in that period 
was 3.7/100 000 population (3.5/100 000 for men, and 3.9/100 
000 for women). The ASR was calculated to be 4.2/100 000 world 
standard population per year (this was similar for men and 
women). 
TABLE I. THE REVISED BETHESDA GUIDELINES 
FOR TESTING COLORECTAL TUMOURS FOR 
MICROSATELLITE INSTABILITY (MSI)6
Tumours from individuals should be tested for MSI 
in the following situations:
1.  Colorectal cancer diagnosed under the age of 
50 years of age
2.  Presence of synchronous, metachronous 
colorectal, or other HNPCC-associated 
tumours,* regardless of age
3.  Colorectal cancer with the MSI-h histology† 
diagnosed in a patient under 60 years of age
4.  Colorectal cancer diagnosed with one or 
more first-degree relatives with an HNPCC-
related tumour, with one of the cancers being 
diagnosed under age 50 years
5.  Colorectal cancer diagnosed in two or more 
first- or second-degree relatives with HNPCC-
related tumour, regardless of age.
*Hereditary non-polyposis colorectal cancer (HNPCC)-related tumours include
colorectal, endometrial, stomach, ovarian, pancreas, bladder, ureter and renal 
pelvis, biliary tract, brain (usually glioblastoma as seen in Turcot syndrome), 
sebaceous gland adenomas and keratoacanthomas in Muir-Torre syndrome, and 
carcinoma of the small bowel.
†Presence of tumour infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, 
mucinous/signet ring differentiation, or medullary growth pattern.
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Age
The median age at which colorectal cancer was diagnosed was 59 
years (range 16 - 90 years). The age of one of the 206 patients was 
unknown. The age distribution is illustrated in Fig. 1. The age of 
diagnosis was lower in men than women (57 v. 61 years, p=0.033). 
Patients treated in the public health sector were diagnosed with 
colorectal cancer at a younger age than those treated in the private 
sector (57 v. 63 years, p=0.024).
Site
The site of the colorectal cancer could be clearly identified by the 
pathology report in 190 cases. Of these tumours, 58 (31%) were 
located in the right side of the colon and 132 (69%) in the left side. 
Subjects who were diagnosed with colorectal cancer before the age 
of 50 years were more likely to have right-sided cancers than those 
who were diagnosed when they were older than 50 (23/48 (48%) v. 
35/141 (25%), p=0.007). The sites of the cancers were similar for 
men and women (p=0.55). The sites of the colorectal cancers are 
shown in Table II.
Stage
Pathological staging information was complete in 125 patients. 
The stage distribution of colorectal cancers is shown in Table III. 
There was no significant difference in stage of diagnosis between 
patients who were cared for in the public and private sectors. 
There was also no difference in stage distribution between males 
and females (p=0.83), younger (<50 years) and older (>50 years) 
subjects (p=0.27), or right- versus left-sided cancers (p=0.63).
Microsatellite instability features 
Table IV shows the frequency of demographic and histological 
features suggestive of microsatellite instability (MSI) in the 
colorectal cancers. Patients were younger than 50 years of age in 
54/205 cases (26%). Patients who were under 50 years were more 
likely to have mucinous tumours than older patients (10/54 (19%) 
v. 11/151 (7%), p=0.038).
On pathological and demographic criteria alone, 75/206 (36%) 
of the patients met at least one of the criteria of the revised 
Bethesda guidelines for MSI testing, and patients treated in the 
public sector were more likely to fulfil these criteria than those 
from the private sector (65/160 (41%) v. 10/46 (22%), p=0.03).
Conclusion 
We found colorectal cancer to be relatively rare in the Northern 
Cape province of South Africa. The annual incidence was 3.7/100 
000 population, with the ASR calculated to be 4.2/100 000. This 
is considerably lower than the incidences reported in First-World 
countries, which range from 45 to 61 cases per 100 000 per year,15,16 
but in keeping with previous studies conducted in Africa, where 
annual incidences from 2 to 11/100 000 have been reported.17-19  
The low incidence of colorectal cancer in this study may be due 
to under-reporting. It is not known how many patients living in 
the Northern Cape may have sought medical care outside that 
province, and these patients would not have been identified in this 
study. Also, the disease may be under-diagnosed. Access to health 
care in the Northern Cape is limited, with a predominantly rural 
population who live in often very remote areas, and there is only 
one trained colonoscopist in practice in the public sector in the 
entire province. This is, however, unlikely to explain the tenfold 
reduction in incidence compared with Western countries. 
The median age of diagnosis of CRC was 59 years, and 54/205 
patients (26%) were under the age of 50 years. This is in keeping 
with other studies in South Africa, Nigeria, Kenya and Ethiopia,7, 
20-22 in which the median ages of diagnosis were between 47 and 
59 years, and is in contrast to reports from America (71 years)16 
and the UK (73 years).23 A shorter life expectancy in African 
countries and different demographics (with more young people 
in the population overall) may partly explain the median age at 
diagnosis, or it may reflect different tumour biology. Similarly, 
we found that patients who were treated in the public sector were 
diagnosed with CRC at a younger age than those in the private 
health system (57 v. 63 years). In South Africa, access to private 
health care may be seen as a marker of affluence and a Western 
lifestyle. Because of the entrenched inequalities in our society, it 
Fig. 1. Age of diagnosis of colorectal cancer in the Northern 
Cape Province.
TABLE II. SITE DISTRIBUTION OF COLORECTAL 
CANCERS
Location N %
Caecum 26 12.6
Ascending colon including 
hepatic flexure 8 3.9
Transverse colon 21 10.2
Descending colon including 
splenic flexure 9 4.4
Sigmoid 38 18.4
Rectosigmoid 7 3.4
Rectum 74 35.9
Right hemicolon* 3 1.5
Left hemicolon* 4 1.9
Unknown 16 7.8
Total cancers 206 100
*The site was not described more specifically than this in the pathology report.
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may also be a marker for racial and therefore genetic difference 
between these groups. The patients’ racial groupings were not 
recorded on the pathology reports, and we made no attempt to 
obtain that information as we felt that that would be a breach of 
the patients’ privacy.
Patients under the age of 50 years were more likely to have 
right-sided and mucinous tumours, suggesting that MSI-h-type 
tumours were more prevalent in the younger patients. In this 
study, 36% of patients overall fulfilled at least one of the revised 
Bethesda guidelines for MSI testing, even without any family 
history being known. These patients will be further investigated 
for possible HNPCC (by taking their family histories, and by 
further immunohistochemical and genetic studies). This may allow 
families with HNPCC (who would benefit from colonoscopic 
surveillance24) to be identified.
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